Annual report pursuant to Section 13 and 15(d)

STOCK BASED COMPENSATION

v2.4.1.9
STOCK BASED COMPENSATION
12 Months Ended
Dec. 31, 2014
STOCK BASED COMPENSATION  
STOCK-BASED COMPENSATION

4. STOCK-BASED COMPENSATION

        Total stock-based compensation expense related to all of our stock-based awards was as follows (in thousands):

                                                                                                                                                                                    

 

 

Year Ended December 31,

 

 

 

2014

 

2013

 

2012

 

Research and development

 

$

4,674 

 

$

3,930 

 

$

7,050 

 

General and administrative

 

 

5,113 

 

 

2,997 

 

 

5,567 

 

Restructuring charges

 

 

 

 

239 

 

 

—  

 

​  

​  

​  

​  

​  

​  

Total stock-based compensation expense

 

$

9,787 

 

$

7,166 

 

$

12,617 

 

​  

​  

​  

​  

​  

​  

​  

​  

​  

​  

​  

​  

​  

        In December 2014, we entered into a severance agreement with our former CEO. As part of the severance arrangement we offered, we extended the date to which our former CEO had the right to exercise his vested options within 90 days from his termination date as was stipulated under his option agreement to the end of the contractual term of the options, of which the remaining contractual term for the most recently granted options is nine years. In addition, we also accelerated the vesting period of certain of his unvested stock options. As a result of these modifications, we recorded incremental stock-based compensation expense of approximately $1.5 million in the fourth quarter of 2014 (see Note 12). This amount is included as part of "General and administrative expense" in the accompanying Statement of Operations.

        In September 2013, we announced that we had reduced our workforce by 18%, or 30 positions, in connection with efforts to prioritize projects and conserve our working capital. As part of the severance arrangement we offered the terminated employees, we extended the date to which the terminated employees had to exercise their vested options to June 30, 2014, rather than 90 days from the termination date as was stipulated under the employee's option agreements. In addition, we also accelerated the vesting period of certain unvested stock options for one terminated employee. As a result of these modifications, we recorded non-cash stock-based compensation expense of $239,000 in the third quarter of 2013. This expense was classified under "Restructuring expense" in the accompanying Statements of Operations. See Note 11 for further discussion regarding this reduction in our workforce.

Employee Stock Option Plans

        In 2012, an amendment to the 2011 Plan was approved primarily to (i) increase the aggregate number of shares of common stock authorized for issuance under the 2011 Plan by 600,000 shares, (ii) provide that the number of shares available for issuance under the 2011 Plan shall be reduced by one share for each share of common stock subject to a stock option or stock appreciation right with a strike price of at least 100% of the fair market value of the underlying common stock on the grant date and by 1.4 (instead of 1.7) shares for each share of common stock subject to any other type of award issued pursuant to the 2011 Plan and (iii) include the Company's Chief Executive Officer as an eligible participant under the 2011 Plan. In 2013, an amendment to the 2011 Plan was approved primarily to (i) increase the aggregate number of shares of common stock authorized for issuance under the 2011 Plan by 7,000,000 shares and (ii) provide that the number of shares available for issuance under the 2011 Plan shall be reduced by one share for each share of common stock subject to a stock option or stock appreciation right and by 1.64 shares for each share of common stock subject to any other type of award issued pursuant to the 2011 Plan. Options granted under our 2011 Plan expire no later than ten years from the date of grant. Options may be granted with different vesting terms from time to time, ranging from zero to five years. As of December 31, 2014, a total of 11,078,887 shares of common stock were authorized for issuance under the 2011 Plan. There were 11,219 options to purchase shares exercised during the year ended December 31, 2014 under the 2011 Plan.

        In 2012, an amendment to the 2000 Plan was approved primarily to (i) extend the term of the 2000 Plan to May 22, 2022, (ii) provide that the number of shares available for issuance under the 2000 Plan shall be reduced by one share for each share of common stock subject to a stock option or stock appreciation right with a strike price of at least 100% of the fair market value of the underlying common stock on the grant date and by 1.4 (instead of 1.7) shares for each share of common stock subject to any other type of award issued pursuant to the 2000 Plan and (iii) increase the maximum amount that may be received by an individual in any calendar year attributable to performance-based stock awards under the 2000 Plan from the value of not more than 166,666 shares of the Company's common stock to the value of not more than 1,500,000 shares of the Company's common stock. In 2013, an amendment to the 2000 Plan was approved primarily to (i) increase the number of shares authorized for issuance under the 2000 Plan by 675,000 shares of common stock and (ii) provide that the number of shares available for issuance under the 2000 Plan shall be reduced by one share for each share of common stock subject to a stock option or stock appreciation right and by 1.64 shares (instead of 1.4 shares) for each share of common stock subject to any other type of award issued pursuant to the 2000 Plan. Options may be granted with different vesting terms from time to time, ranging from zero to five years. As of December 31, 2014, a total of 12,299,675 shares of common stock were authorized for issuance under the 2000 Plan. There were no options to purchase shares exercised during the year ended December 31, 2014 under the 2000 Plan.

        In 2013, an amendment to the Directors' Plan was approved primarily to increase the number of shares authorized for issuance under the Directors' Plan by 100,000 shares of common stock to an aggregate total of 1,235,000 shares. The exercise price of options under the Directors' Plan is equal to the fair market value of the common stock on the date of grant. The maximum term of the options granted under the Directors' Plan is ten years. As of December 31, 2014, a total of 1,188,182 shares of common stock were authorized for issuance under the Directors' Plan. There were no options to purchase shares exercised during the year ended December 31, 2014 under the Directors' Plan.

        Pursuant to FASB ASC 718, we are required to estimate the amount of expected forfeitures when calculating compensation costs. We estimated the forfeiture rate using our historical experience with nonvested options. We adjust our stock-based compensation expense as actual forfeitures occur, review our estimated forfeiture rates each quarter and make changes to our estimate as appropriate.

        The fair value of each option award is estimated on the date of grant using the Black-Scholes option pricing model. We have segregated option awards into the following three homogenous groups for the purposes of determining fair values of options: officers and directors, all other employees, and consultants.

        We determined weighted-average valuation assumptions separately for each of these groups as follows:

·

Volatility—We estimated volatility using the historical share price performance over the expected life of the option up to the point where we have historical market data. We also considered other factors, such as implied volatility, our current clinical trials and other company activities that may affect the volatility of our stock in the future. We determined that at this time historical volatility is more indicative of our expected future stock performance than implied volatility.

·

Expected term—For options granted to consultants, we use the contractual term of the option, which is generally ten years, for the initial valuation of the option and the remaining contractual term of the option for the succeeding periods. We worked with various historical data to determine the applicable expected term for each of the other option groups. This data included: (1) for exercised options, the term of the options from option grant date to exercise date; (2) for cancelled options, the term of the options from option grant date to cancellation date, excluding nonvested option forfeitures; and (3) for options that remained outstanding at the balance sheet date, the term of the options from option grant date to the end of the reporting period and the estimated remaining term of the options. The consideration and calculation of the above data gave us reasonable estimates of the expected term for each employee group. We also considered the vesting schedules of the options granted and factors surrounding exercise behavior of the option groups, our current market price and company activity that may affect our market price. In addition, we considered the optionee type (i.e., officers and directors or all other employees) and other factors that may affect the expected term of the option.

·

Risk-free interest rate—The risk-free interest rate is based on U.S. Treasury constant maturity rates with similar terms to the expected term of the options for each option group.

·

Dividend yield—The expected dividend yield is 0% as we have not paid and do not expect to pay dividends in the future.

        The following table summarizes the weighted-average assumptions relating to options granted pursuant to our equity incentive plans for the years ended December 31, 2014, 2013 and 2012:

                                                                                                                                                                                    

 

 

Equity Incentive
Plans

 

 

 

Year Ended
December 31,

 

 

 

2014

 

2013

 

2012

 

Risk-free interest rate

 

 

2.2 

%

 

1.1 

%

 

0.9 

%

Expected term (in years)

 

 

6.5 

 

 

5.4 

 

 

5.5 

 

Dividend yield

 

 

0.0 

%

 

0.0 

%

 

0.0 

%

Expected volatility

 

 

74.4 

%

 

72.2 

%

 

81.5 

%

        The exercise price of stock options is determined to be the market price of our common stock on the date immediately preceding the date of grant. These stock options become exercisable at varying dates and generally expire ten years from the date of grant. At December 31, 2014, options to purchase 7,596,071 shares of common stock were available for grant and 24,566,744 reserved shares of common stock were available for future issuance under our stock option plans.

        We recorded stock-based compensation expense of approximately $38,000, $36,000 and $55,000 for the years ended December 31, 2014, 2013 and 2012, respectively, associated with options granted to consultants reflecting the fair value valuation and periodic fair value re-measurement of outstanding consultant options subject to vesting under FASB ASC 505-50. The valuation is based upon the current fair value of our common stock and other assumptions, including the expected future volatility of our stock price, risk-free interest rate and expected term. We amortized stock- based compensation related to consultants using a straight-line attribution method consistent with the method used for employees and with the attribution election we made upon adoption of FASB ASC 718. No stock options granted to consultants were exercised during the year ended December 31, 2014.

Stock-Based Compensation Award Activity

        Option activity under our equity incentive plans was as follows:

                                                                                                                                                                                    

 

 

Shares
Available
For Grant

 

Number of
Shares
Underlying
Options

 

Weighted-
Average
Exercise Price

 

Weighted-
Average
Remaining
Contractual
Term
(in years)

 

Aggregate
Intrinsic
Value

 

Outstanding at January 1, 2012

 

 

4,707,753

 

 

11,749,359

 

$

12.07

 

 

 

 

 

 

 

​  

​  

​  

​  

Authorized for grant

 

 

600,000

 

 

 

 

 

 

 

 

 

 

 

 

Granted

 

 

(2,149,266

)

 

2,149,266

 

$

8.13

 

 

 

 

 

 

 

Exercised

 

 

 

 

(254,149

)

$

7.08

 

 

 

 

 

 

 

Cancelled

 

 

40,099

 

 

(40,099

)

$

19.60

 

 

 

 

 

 

 

​  

​  

​  

​  

Outstanding at December 31, 2012

 

 

3,198,586

 

 

13,604,377

 

$

11.52

 

 

 

 

 

 

 

​  

​  

​  

​  

Authorized for grant

 

 

7,775,000

 

 

 

 

 

 

 

 

 

 

 

 

Granted

 

 

(3,140,956

)

 

3,140,956

 

$

5.46

 

 

 

 

 

 

 

Exercised

 

 

 

 

 

$

 

 

 

 

 

 

 

Cancelled

 

 

1,213,131

 

 

(1,213,131

)

$

8.26

 

 

 

 

 

 

 

​  

​  

​  

​  

Outstanding at December 31, 2013

 

 

9,045,761

 

 

15,532,202

 

$

10.55

 

 

 

 

 

 

 

​  

​  

​  

​  

​  

​  

​  

​  

​  

Authorized for grant

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Granted

 

 

(3,467,120

)

 

3,467,120

 

$

3.39

 

 

 

 

 

 

 

Exercised

 

 

 

 

(11,219

)

$

3.44

 

 

 

 

 

 

 

Cancelled

 

 

2,017,430

 

 

(2,017,430

)

$

10.75

 

 

 

 

 

 

 

​  

​  

​  

​  

Outstanding at December 31, 2014

 

 

7,596,071

 

 

16,970,673

 

$

9.07

 

 

5.79

 

$

25,140

 

​  

​  

​  

​  

​  

​  

​  

​  

​  

Vested and expected to vest at December 31, 2014

 

 

 

 

 

16,861,378

 

$

9.10

 

 

 

 

 

 

 

​  

​  

​  

​  

​  

Exercisable at December 31, 2014

 

 

 

 

 

14,243,893

 

$

10.09

 

 

5.19

 

$

983

 

​  

​  

​  

​  

​  

Exercisable at December 31, 2013

 

 

 

 

 

13,246,612

 

$

11.44

 

 

 

 

 

 

 

​  

​  

​  

​  

​  

Exercisable at December 31, 2012

 

 

 

 

 

12,841,378

 

$

11.75

 

 

 

 

 

 

 

​  

​  

​  

​  

​  

        Of the 3,467,120 common stock options granted during 2014, 950,000 shares were related to performance-based stock option awards, of which only 700,000 shares are still outstanding due to the cancellation of the 250,000 shares in the fourth quarter of 2014, which will vest upon the achievement of certain corporate performance-based milestones related to the progress and success of the Phase 3 clinical program of fostamatinib in ITP. Weighted-average grant date fair value of options granted during 2014, 2013 and 2012 was $2.32, $3.34 and $5.44, respectively.

        The aggregate intrinsic value in the table above is calculated as the difference between the exercise price of the underlying awards and the quoted price of our common stock for the options that were in-the-money at December 31, 2014. At December 31, 2014 and 2013, we had 2,726,779 and 2,281,966, respectively, of nonvested stock options, with approximately $24,000 and $14,000 intrinsic value at December 31, 2014 and 2013, respectively. During the years ended December 31, 2014 and 2012, aggregate intrinsic value of options exercised under our stock option plans was approximately $10,000 and $701,000, respectively, determined as of the date of option exercise. There were no options exercised during the year ended December 31, 2013.

        As of December 31, 2014, there was approximately $4.8 million of total unrecognized compensation cost, net of estimated forfeitures, related to nonvested stock-based compensation arrangements granted under our stock option plans and approximately $302,000 of total unamortized compensation cost related to our Purchase Plan. The unamortized compensation cost related to our stock option plans and our Purchase Plan is expected to be recognized over a weighted- average period of approximately 1.9 years and 1.7 years, respectively. For the years ended December 31, 2014 and 2013, there were 2,456,622 and 1,513,339 shares vested with weighted-average exercise price of $4.74 and $6.64, respectively.

        Details of our stock options by exercise price are as follows as of December 31, 2014:

                                                                                                                                                                                    

 

 

Options Outstanding

 

Options Exercisable

 

Exercise Price

 

Number of
Outstanding
Options

 

Weighted-
Average
Remaining
Contractual
Life
(in years)

 

Weighted-
Average
Exercise
Price

 

Number of
Options

 

Weighted-
Average
Exercise
Price

 

$1.68 - $3.55

 

 

2,317,779 

 

 

8.77 

 

$

3.29 

 

 

1,112,849 

 

$

3.36 

 

$3.59 - $6.49

 

 

3,300,357 

 

 

6.80 

 

 

4.99 

 

 

2,050,668 

 

 

5.84 

 

$6.51 - $6.55

 

 

2,207,938 

 

 

7.53 

 

 

6.52 

 

 

1,991,664 

 

 

6.52 

 

$6.73 - $7.40

 

 

2,196,855 

 

 

5.32 

 

 

6.85 

 

 

2,187,713 

 

 

6.85 

 

$7.53 - $8.27

 

 

2,132,765 

 

 

6.42 

 

 

8.11 

 

 

2,091,925 

 

 

8.11 

 

$8.34 - $11.73

 

 

2,528,537 

 

 

3.52 

 

 

10.29 

 

 

2,522,633 

 

 

10.29 

 

$15.49 - $24.56

 

 

1,132,244 

 

 

0.96 

 

 

23.41 

 

 

1,132,244 

 

 

23.41 

 

$26.45

 

 

1,154,198 

 

 

3.08 

 

 

26.45 

 

 

1,154,198 

 

 

26.45 

 

​  

​  

​  

​  

$1.68 - $26.45

 

 

16,970,673 

 

 

5.79 

 

 

9.07 

 

 

14,243,894 

 

$

10.09 

 

​  

​  

​  

​  

​  

​  

​  

​  

​  

Employee Stock Purchase Plan

        In August 2000, we adopted our Purchase Plan which was approved in September 2000 by our stockholders. In 2014, an amendment to the Purchase Plan was approved primarily to increase the number of shares authorized for issuance under the Directors' Plan by 4,000,000 shares of common stock. The Purchase Plan permits eligible employees to purchase common stock at a discount through payroll deductions during defined offering periods. The price at which the stock is purchased is equal to the lesser of 85% of the fair market value of the common stock on the first day of the offering or 85% of the fair market value of our common stock on the purchase date. The initial offering period commenced on the effective date of our initial public offering. We issued 505,877, 383,717 and 269,681 shares of common stock during 2014, 2013 and 2012, respectively, pursuant to the Purchase Plan at an average price of $2.24, $2.74 and $5.81, respectively. For 2014, 2013 and 2012, the weighted average fair value of stock purchased under the Purchase Plan was $1.42, $2.05 and $3.42, respectively. As of December 31, 2014, we had 3,578,153 reserved shares of common stock available for future issuance under the Purchase Plan.

        The fair value of awards granted under our Purchase Plan is estimated on the date of grant using the Black-Scholes option pricing model, which uses weighted- average assumptions. Our Purchase Plan provides for a twenty-four month offering period comprised of four six-month purchase periods with a look-back option. A look-back option is a provision in our Purchase Plan under which eligible employees can purchase shares of our common stock at a price per share equal to the lesser of 85% of the fair market value on the first day of the offering period or 85% of the fair market value on the purchase date. Our Purchase Plan also includes a feature that provides for a new offering period to begin when the fair market value of our common stock on any purchase date during an offering period falls below the fair market value of our common stock on the first day of such offering period. This feature is called a "reset." Participants are automatically enrolled in the new offering period. We had a "reset" on January 2, 2014 because the fair market value of our stock on December 31, 2013 was lower than the fair market value of our stock on July 1, 2013, the first day of the offering period. We applied modification accounting in accordance with ASC Topic No. 718, Stock Compensation, to determine the incremental fair value associated with this Purchase Plan "reset" and will recognize the related stock-based compensation expense according to FASB ASC Subtopic No. 718-50, Employee Share Purchase Plan. The total incremental fair value for this Purchase Plan "reset" was approximately $577,000, that will be recognized from January 2, 2014 to December 31, 2015. On January 2, 2015, we had another "reset" because the fair market value of our stock on December 31, 2014 was lower than the fair market value of our stock on July 1, 2014, the first day of another offering period. We applied modification accounting in accordance with the relevant guidance and determined that the incremental fair value associated with this Purchase Plan "reset" was approximately $792,000 that will be recognized from January 2, 2015 to December 31, 2016.

        The following table summarizes the weighted-average assumptions related to our Purchase Plan for the years ended December 31, 2014, 2013 and 2012. Expected volatilities for our Purchase Plan are based on the two-year historical volatility of our stock. Expected term represents the weighted- average of the purchase periods within the offering period. The risk-free interest rate for periods within the expected term is based on U.S. Treasury constant maturity rates.

                                                                                                                                                                                    

 

 

Employee Stock
Purchase Plan

 

 

 

Year Ended
December 31,

 

 

 

2014

 

2013

 

2012

 

Risk-free interest rate

 

 

0.3 

%

 

0.2 

%

 

0.2 

%

Expected term (in years)

 

 

1.7 

 

 

1.4 

 

 

1.2 

 

Dividend yield

 

 

0.0 

%

 

0.0 

%

 

0.0 

%

Expected volatility

 

 

66.0 

%

 

64.4 

%

 

47.4 

%